3 results
To assess if short antibiotic treatment (3x24 hours) with an anti-pseudomonal carbapenem (imipenem-cilastatin or meropenem) is safe (NON-INFERIOR) with regard to treatment failure in comparison with extended treatment (at least 9x24hours) of high-…
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.
The objectiveof this study is to evaluate the short term clinical applicability of the Provox Vega HP and to investigate its potential limitations and benefits. As a result of the evaluations, the design could be adapted to arrive at the optimal…